Santa Barbara, Calif. - Inamed Corporation and its partner Ipsen,a European pharmaceutical company, reported results of a Phase II dosingstudy of their botulinum toxin type A product yesterday at the AAD meeting.
Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
Derm In The News: September 24-30
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis
Evaluating Efficacy of Trifarotene in Latin American Patients With Acne
2 Clarke Drive Cranbury, NJ 08512